Publications by authors named "C Muhn"
Article Synopsis
- Aging leads to increased prominence of the platysma muscle, causing noticeable neck bands and a less defined jawline.
- A phase 2 study tested onabotulinumtoxinA in adults with significant platysma prominence, comparing low and high doses against a placebo, with follow-up after 4 months.
- Results showed that both treatment groups had a significant improvement in appearance, with most side effects being mild and related to the procedure, indicating onabotulinumtoxinA is a well-tolerated and effective treatment for platysma prominence.
The severe acute respiratory syndrome coronavirus 2 pandemic has necessitated enhanced protection against viral transmission among healthcare professionals, particularly relating to handwashing and personal protective equipment. Some of these requirements may persist for years to come. They bring associated concerns around skin hygiene and general care, with damage to the face and hands now a well-documented consequence among healthcare professionals.
View Article and Find Full Text PDFBackground: Injectable daxibotulinumtoxinA (RT002) is an investigational botulinum toxin Type A. Published Phase 2 data show that, compared with 20U onabotulinumtoxinA, 40U daxibotulinumtoxinA is associated with a significantly greater response rate and significantly longer duration of response (median 24 weeks), and appears generally safe and well tolerated (www.clinicaltrials.
View Article and Find Full Text PDFBackground: Injectable daxibotulinumtoxinA (RT002) is an investigational botulinum toxin Type A in clinical development. It is formulated with a proprietary peptide and offers the potential of a longer acting neurotoxin therapy.
Objective: To compare the safety, efficacy, and duration of response of daxibotulinumtoxinA with onabotulinumtoxinA and placebo [www.
Background: Various onabotulinumtoxinA doses are effective in treating forehead lines (FHL), with a trend toward lower doses.
Objective: To evaluate efficacy and safety of onabotulinumtoxinA dose-ranging treatment of FHL when the frontalis area and glabellar complex are treated together.
Materials And Methods: Adults with moderate-to-severe FHL received onabotulinumtoxinA 40 U (FHL, 20 U; glabellar lines [GL], 20 U), 30 U (FHL, 10 U; GL, 20 U), or placebo.